Session II: Cancer of the Pancreas

SO-2: Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study

Wednesday, June 29, 2022

14:50 – 14:58

Location: Auditorium A; Level 0

Abstract Presenter(s)

Paul Ross, PhD FRCP

Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom